image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 132.7683
-1.14 %
$ 19.5 B
Market Cap
12.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BIIB stock under the worst case scenario is HIDDEN Compared to the current market price of 133 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BIIB stock under the base case scenario is HIDDEN Compared to the current market price of 133 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BIIB stock under the best case scenario is HIDDEN Compared to the current market price of 133 USD, Biogen Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIIB

image
$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
9.68 B REVENUE
-1.62%
2.22 B OPERATING INCOME
5.80%
1.63 B NET INCOME
40.53%
2.88 B OPERATING CASH FLOW
85.85%
-799 M INVESTING CASH FLOW
80.51%
-684 M FINANCING CASH FLOW
-457.80%
2.43 B REVENUE
-0.97%
625 M OPERATING INCOME
38.75%
240 M NET INCOME
-9.82%
259 M OPERATING CASH FLOW
-65.92%
-47.3 M INVESTING CASH FLOW
-154.30%
-23 M FINANCING CASH FLOW
-291.14%
Balance Sheet Biogen Inc.
image
Current Assets 7.46 B
Cash & Short-Term Investments 2.38 B
Receivables 1.87 B
Other Current Assets 3.21 B
Non-Current Assets 20.6 B
Long-Term Investments 227 M
PP&E 3.54 B
Other Non-Current Assets 16.8 B
8.47 %6.66 %11.45 %12.61 %59.99 %Total Assets$28.0b
Current Liabilities 5.53 B
Accounts Payable 424 M
Short-Term Debt 1.75 B
Other Current Liabilities 3.36 B
Non-Current Liabilities 5.8 B
Long-Term Debt 4.88 B
Other Non-Current Liabilities 923 M
3.74 %15.43 %29.61 %43.07 %8.14 %Total Liabilities$11.3b
EFFICIENCY
Earnings Waterfall Biogen Inc.
image
Revenue 9.68 B
Cost Of Revenue 2.31 B
Gross Profit 7.37 B
Operating Expenses 5.15 B
Operating Income 2.22 B
Other Expenses 587 M
Net Income 1.63 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b(2b)7b(5b)2b(587m)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
76.12% GROSS MARGIN
76.12%
22.93% OPERATING MARGIN
22.93%
16.87% NET MARGIN
16.87%
9.76% ROE
9.76%
5.82% ROA
5.82%
7.83% ROIC
7.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biogen Inc.
image
7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.63 B
Depreciation & Amortization 673 M
Capital Expenditures -360 M
Stock-Based Compensation 291 M
Change in Working Capital -155 M
Others 517 M
Free Cash Flow 2.52 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biogen Inc.
image
Wall Street analysts predict an average 1-year price target for BIIB of $245 , with forecasts ranging from a low of $118 to a high of $342 .
BIIB Lowest Price Target Wall Street Target
118 USD -11.12%
BIIB Average Price Target Wall Street Target
245 USD 84.87%
BIIB Highest Price Target Wall Street Target
342 USD 157.59%
Price
Max Price Target
Min Price Target
Average Price Target
350350300300250250200200150150100100Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Biogen Inc.
image
Sold
0-3 MONTHS
481 K USD 1
3-6 MONTHS
1.31 M USD 1
6-9 MONTHS
17.3 K USD 1
9-12 MONTHS
88 K USD 1
Bought
152 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. globenewswire.com - 1 week ago
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise globenewswire.com - 2 weeks ago
Outside Days Offer Intriguing Options Opportunity Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX). schaeffersresearch.com - 1 month ago
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. seekingalpha.com - 1 month ago
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal Paris,  May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. globenewswire.com - 1 month ago
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year. zacks.com - 1 month ago
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priya Singhal - Head, Development Robin Kramer - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Tim Anderson - Bank of America Chris Schott - JPMorgan Michael Yee - Jefferies Mike DiFiore - Evercore ISI Terence Flynn - Morgan Stanley Geoff Meacham - Citibank Operator Good morning. My name is Melinda, and I'll be your conference operator today. seekingalpha.com - 1 month ago
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. zacks.com - 1 month ago
Biogen beats quarterly profit estimates on strong demand for rare disease drugs Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs. reuters.com - 1 month ago
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com - 1 month ago
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week. zacks.com - 1 month ago
8. Profile Summary

Biogen Inc. BIIB

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 19.5 B
Dividend Yield 0.00%
Description Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Contact 225 Binney Street, Cambridge, MA, 02142 https://www.biogen.com
IPO Date Sept. 17, 1991
Employees 7605
Officers Ms. Nicole Murphy Executive Vice President and Head of Pharmaceutical Operations & Technology Mr. Sean Godbout Chief Accounting Officer & Global Corporate Controller Mr. Tim Power M.B.A., Ph.D. Head of Investor Relations Mr. Adam Keeney Ph.D. Executive Vice President & Head of Corporate Development Ms. Robin C. Kramer Executive Vice President & Chief Financial Officer Dr. Priya Singhal M.D., M.P.H. Executive Vice President & Head of Development Mr. Christopher A. Viehbacher President, Chief Executive Officer & Director Ms. Susan H. Alexander Esq. Executive Vice President & Chief Legal Officer Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs Dr. Ginger Gregory Ph.D. Executive Vice President & Chief Human Resources Officer